OrbiMed’s Apellis Pharmaceuticals APLS Stock Holding History

OrbiMed’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-250,000	Closed	-$5.66M	–	111
2025 Q3	$5.66M	Buy	250,000 +200,000	+400%	+$4.66M	0.13%	84
2025 Q2	$866K	Buy	+50,000	New	+$926K	0.02%	95
2024 Q2	–	Sell	-150,000	Closed	-$8.82M	–	115
2024 Q1	$8.82M	Buy	+150,000	New	+$9.56M	0.16%	84
2023 Q4	–	Sell	-77,500	Closed	-$2.95M	–	114
2023 Q3	$2.95M	Buy	+77,500	New	+$3.4M	0.06%	107
2019 Q3	–	Sell	-75,000	Closed	-$1.9M	–	120
2019 Q2	$1.9M	Hold	75,000	–	–	0.03%	122
2019 Q1	$1.46M	Buy	+75,000	New	+$1.18M	0.02%	118

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed's APLS Position: Q1 2026 in Review

OrbiMed sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 2,429,868 shares — an estimated $61M sold.

OrbiMed first reported a position in APLS in Q4 2018 and held it in 16 quarters. The position peaked at $82.9M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

OrbiMed reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
OrbiMed sold 2,429,868 Apellis Pharmaceuticals shares in Q1 2026, an estimated $61M.
OrbiMed first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 16 quarters.
OrbiMed's Apellis Pharmaceuticals position peaked at $82.9M in Q2 2023.
321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.